Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 8Neuroendocrine Tumors 2Neoplasm Metastasis 2Liver Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Sarcoma 1Recurrence 1Rectal Neoplasms 1Ovarian Neoplasms 1Liver Malignancy 1Hepatic Malignancies 1Carcinoma, Ovarian Epithelial 1Bile Duct Neoplasms 1

Interventions

Fluorouracil 219Leucovorin 202Oxaliplatin 192Irinotecan 150Bevacizumab 110Capecitabine 94Cetuximab 90Folfox protocol 54Chemotherapy, Adjuvant 36Panitumumab 30Colonoscopy 30pembrolizumab 23Drug Therapy 23Nivolumab 22Magnetic Resonance Spectroscopy 22Gemcitabine 21Blood Specimen Collection 20Radiotherapy 19Floxuridine 19Biopsy 19Neoadjuvant Therapy 18Laparoscopy 18IFL protocol 18Early Intervention, Educational 18Celecoxib 18Surveys and Questionnaires 17Surgical Procedures, Operative 16Immunohistochemistry 16Exercise 16trifluridine tipiracil drug combination 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colonic Neoplasms × Yttrium-90 × Clear all
NCT04108481 2025-03-28

iRE-C

University of Iowa

Phase 1 Terminated
5 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00766220 2013-01-03

Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡